Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$176.64 USD

176.64
9,476,916

+1.92 (1.10%)

Updated Aug 15, 2025 04:00 PM ET

After-Market: $177.00 +0.36 (0.20%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (61 out of 246)

Industry: Large Cap Pharmaceuticals

Zacks News

Kinjel Shah headshot

Pharma Stock Roundup: JNJ's Q1 Earnings, Coronavirus Product Development Efforts

J&J (JNJ) announces Q1 results. Several companies offer update on their studies/plans to make coronavirus treatments or vaccines

Sanghamitra Saha headshot

Optimism Back in Wall Street? ETFs Areas to Win the Most

Wall Street is likely to stage a relief rally on hopes of reopening of American businesses, improving virus outlook and chances of treatment coming on stream.

Ritujay Ghosh headshot

Gilead Brings Likely Coronavirus Cure, Pharma Rallies on R&D

Shares of Gilead Science Inc. (GILD) rally on media reports that severe coronavirus patients were responding positively to the company's experimental treatment, remdesivir.

Sheraz Mian headshot

Q1 Earnings Scorecard and Analyst Reports for Netflix, Costco & Others

In addition to new research reports on 16 major stocks, including Netflix (NFLX), Costco (COST) and others, we also have real-time Q1 earnings scorecard today.

Sweta Killa headshot

What's in Store for Dow ETFs in Q1 Earnings?

With most blue-chip companies' earnings scheduled over the coming weeks, investors should closely monitor the movement of the Dow ETF.

Kinjel Shah headshot

Pharma Q1 Earnings Begin With J&J's Report: 3 Stocks to Buy

Investors typically look at J&J's (JNJ) results for signals about how the rest of the big drugmakers will fare.

Sweta Killa headshot

JNJ Beats, Cuts View on Coronavirus: Healthcare ETFs in Focus

Investors should closely watch the movement of the stock and keep a close eye on ETFs having double-digit allocation to this diversified drug maker post its earnings release.

Zacks Equity Research

Stock Market News for Apr 15, 2020

Benchmarks closed higher on Tuesday as investors remained optimistic that the U.S. economy may open soon. The coronavirus pandemic had compelled the government to take protective measures including lockdowns.

Ritujay Ghosh headshot

Pharma Stocks Rally on Sanofi, GSK Coronavirus Vaccine Tie-Up

If successful, the Sanofi (SNY) and GlaxoSmithKline plc (GSK) vaccine would be available in the second half of 2021. Shares of drugmakers jumped on the news.

Benjamin Rains headshot

Buy Abbott (ABT) Stock Ahead of Earnings on Coronavirus Testing Push?

The FDA has approved two different Abbott coronavirus tests. So now the question for investors is should they consider buying ABT shares with the firm set to report its Q1 fiscal 2020 financial results on Thursday, April 16?

Mark Vickery headshot

JPMorgan, Wells Fargo Miss; J&J Beats in Q1

Market futures are up this morning, eager to erase yesterday's losses and apparently not impeded by what they've seen from earnings reports thus far today.

Zacks Equity Research

Major Banks Report Q1 Earnings

Major Banks Report Q1 Earnings

Zacks Equity Research

J&J (JNJ) Beats on Q1 Earnings, Cuts View on Coronavirus Impact

J&J (JNJ) beats estimates for both earnings and sales in the first quarter of 2020. It lowers its adjusted earnings and sales outlook for 2020 for coronavirus-related uncertainty. Stock up.

Ekta Bagri headshot

Will Stem Cell Therapies Aid in Fight Against Coronavirus?

With the coronavirus outbreak gaining steam worldwide, pharma/biotech companies are evaluating every possible therapy to combat the spread.

Zacks Equity Research

Johnson & Johnson (JNJ) Q1 Earnings and Revenues Surpass Estimates

Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 13.30% and 7.48%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

BioCryst Begins Study on Galidesivir for Coronavirus Infection

BioCryst (BCRX) starts recruitment for a clinical study on its pipeline candidate galidesivir to treat patients with the deadly coronavirus disease.

Zacks Equity Research

Will J&J's Pharma Unit Perform Above Market to Drive Q1 Result?

J&J's (JNJ) Pharma segment is delivering an above-market performance despite currency headwinds and the impact of biosimilar and generic competition.

Mark Vickery headshot

Big Week of Q1 Earnings Coming Up

Starting with the big banks and moving to companies working of a vaccine for COVID-19, we'll hope for the best and expect the worst.

Zacks Equity Research

JPMorgan, Bank of America, Citigroup, Johnson & Johnson and Kansas City Southern are part of Zacks Earnings Preview

JPMorgan, Bank of America, Citigroup, Johnson & Johnson and Kansas City Southern are part of Zacks Earnings Preview

Zacks Equity Research

Gilead Reports Promising Data on Experimental Coronavirus Drug

Gilead (GILD) reports encouraging data on investigational antiviral, remdesivir, in patients hospitalized with COVID-19.

Zacks Equity Research

Q1 Earnings in Focus

Q1 Earnings in Focus

Neena Mishra headshot

Coronavirus Testing, Vaccines & Treatments: What You Should Know

We discuss latest developments in tests, vaccines and therapies for COVID-19.

Zacks Equity Research

Novovax Up on Rapid Progress of Coronavirus Vaccine Candidate

Novovax (NVAX) announces plans to initiate clinical study to evaluate its coronavirus vaccine candidate in May, weeks ahead of schedule.

Zacks Equity Research

J&J (JNJ) Q1 Earnings May Indicate Coronavirus Impact on Pharma

Investor focus is likely to be on the impact of the coronavirus outbreak on J&J's (JNJ) performance when it reports first-quarter results.

    Kevin Cook headshot

    Bull of the Day: Penumbra (PEN)

    This $5 billion innovator removes blood clots and the deadly shadow of stroke with catheter-based aspiration technologies